Zacks Investment Research downgraded shares of Entellus Medical, Inc. (NASDAQ:ENTL) from a buy rating to a hold rating in a research report report published on Tuesday.
According to Zacks, “Entellus Medical, Inc. is a medical technology company. It is engaged in the designing, development and commercialization of products for the treatment of chronic sinusitis. The company operates primarily in the United States and Canada. Entellus Medical, Inc. is headquartered in Plymouth, Minnesota. “
ENTL has been the topic of a number of other research reports. Piper Jaffray Companies reissued a buy rating and issued a $21.00 target price on shares of Entellus Medical in a report on Tuesday, August 22nd. BidaskClub raised Entellus Medical from a hold rating to a buy rating in a report on Saturday, August 19th. Finally, Canaccord Genuity reaffirmed a hold rating and set a $17.00 price target on shares of Entellus Medical in a report on Tuesday, October 17th. Two analysts have rated the stock with a sell rating, three have given a hold rating and five have assigned a buy rating to the stock. The stock currently has a consensus rating of Hold and a consensus target price of $21.86.
Shares of Entellus Medical (NASDAQ ENTL) traded up $0.60 during midday trading on Tuesday, reaching $17.24. 115,846 shares of the company’s stock were exchanged, compared to its average volume of 131,269. The company has a quick ratio of 3.53, a current ratio of 3.87 and a debt-to-equity ratio of 0.19.
Entellus Medical (NASDAQ:ENTL) last issued its earnings results on Thursday, August 3rd. The medical technology company reported ($0.37) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.34) by ($0.03). Entellus Medical had a negative return on equity of 60.10% and a negative net margin of 31.24%. The business had revenue of $22.10 million during the quarter, compared to the consensus estimate of $21.87 million. During the same period in the prior year, the business earned ($0.27) EPS. The business’s revenue was up 18.0% on a year-over-year basis. equities analysts expect that Entellus Medical will post -1.62 EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: “Entellus Medical, Inc. (ENTL) Downgraded by Zacks Investment Research” was first published by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of U.S. & international trademark & copyright law. The correct version of this piece of content can be accessed at https://sportsperspectives.com/2017/11/03/entellus-medical-inc-entl-downgraded-by-zacks-investment-research.html.
In other news, Director Brian E. Farley sold 40,000 shares of Entellus Medical stock in a transaction that occurred on Wednesday, October 4th. The stock was sold at an average price of $19.78, for a total transaction of $791,200.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, VP Timothy B. Petrick sold 2,000 shares of Entellus Medical stock in a transaction that occurred on Friday, September 22nd. The shares were sold at an average price of $18.00, for a total value of $36,000.00. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 92,150 shares of company stock worth $1,740,652. Corporate insiders own 7.70% of the company’s stock.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Nationwide Fund Advisors increased its stake in shares of Entellus Medical by 61.7% during the second quarter. Nationwide Fund Advisors now owns 6,903 shares of the medical technology company’s stock valued at $114,000 after acquiring an additional 2,635 shares during the period. Bank of America Corp DE increased its stake in shares of Entellus Medical by 53.8% during the first quarter. Bank of America Corp DE now owns 7,418 shares of the medical technology company’s stock valued at $102,000 after acquiring an additional 2,594 shares during the period. First Mercantile Trust Co. increased its stake in shares of Entellus Medical by 45.3% during the second quarter. First Mercantile Trust Co. now owns 8,206 shares of the medical technology company’s stock valued at $136,000 after acquiring an additional 2,557 shares during the period. Parametric Portfolio Associates LLC increased its stake in shares of Entellus Medical by 5.6% during the first quarter. Parametric Portfolio Associates LLC now owns 10,888 shares of the medical technology company’s stock valued at $150,000 after acquiring an additional 573 shares during the period. Finally, Kopp Investment Advisors LLC increased its stake in shares of Entellus Medical by 0.5% during the second quarter. Kopp Investment Advisors LLC now owns 11,874 shares of the medical technology company’s stock valued at $197,000 after acquiring an additional 55 shares during the period. Institutional investors and hedge funds own 70.34% of the company’s stock.
About Entellus Medical
Entellus Medical, Inc is a medical technology company. The Company is focused on delivering patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Its three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat (ENT), physicians to perform a range of procedures in the ENT physician office and to simplify operating room-based treatment.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Entellus Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entellus Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.